Polymorphic hydroxylation of Debrisoquine in man

Area of Science:

• Pharmacogenetics
• Drug Metabolism
• Human Genetics

Background:

• Debrisoquine is an antihypertensive drug.
• Its metabolism involves 4-hydroxylation, producing 4-hydroxydebrisoquine.
• Variations in drug metabolism can affect treatment efficacy and safety.

Purpose of the Study:

• To investigate the metabolic profile of debrisoquine in humans.
• To determine the genetic basis for debrisoquine 4-hydroxylation.
• To identify potential genetic polymorphisms affecting drug metabolism.

Main Methods:

• Urine samples from 94 volunteers were analyzed after a single 10 mg oral dose of debrisoquine.
• Quantification of debrisoquine and its primary metabolite, 4-hydroxydebrisoquine.
• Family studies were conducted to assess the inheritance pattern.

Main Results:

• The ratio of debrisoquine to 4-hydroxydebrisoquine in urine showed a bimodal distribution.
• Family studies indicated that debrisoquine 4-hydroxylation is controlled by a single autosomal gene.
• A defect in this metabolic pathway is associated with a recessive allele.

Conclusions:

• The metabolism of debrisoquine is subject to genetic control.
• A single autosomal gene with a recessive allele likely regulates debrisoquine 4-hydroxylation.
• This finding has implications for understanding inter-individual variability in drug response and guiding pharmacogenetic research.